home / stock / immx / immx news

IMMX News and Press, Immix Biopharma Inc. From 05/03/23

Stock Information
Company Name: Immix Biopharma Inc.
Stock Symbol: IMMX
Market: NASDAQ
Website: immixbio.com
Menu
IMMX IMMX Quote IMMX Short IMMX News IMMX Articles IMMX Message Board
Get IMMX Alerts

News, Short Squeeze, Breakout and More Instantly...
IMMX - Immix stock slumps ~20% amid interim data for IMX-110 in colorectal cancer

2023-05-03 09:05:24 ET Immix Biopharma ( NASDAQ: IMMX ) reported early interim data from a phase 1b/2a trial of IMX-110 in combination with Novartis ( NYSE: NVS ) and BeiGene's ( NASDAQ: BGNE ) tislelizumab to treat patients with advanced metastatic co...
IMMX - EL, NNOX and LEJU among pre-market losers

2023-05-03 08:28:28 ET Guardforce AI GFAI -60% raises $8M through equity offering priced at $4.65, shares down 58%. VCI Global Limited ( VCIG ) -50% . Actelis Networks ( ASNS ) -45% . Leju Holdings Limited ( LEJU ) -30% . Minim ( MINM ) ...

IMMX - Immix Biopharma Announces Early Positive IMX-110 Interim Clinical Trial Data Demonstrating 100% Tumor Shrinkage in Advanced Metastatic Colorectal Cancer at the Lowest Dose of IMX-110 + BeiGene / Novartis Anti-PD-1 Antibody Tislelizumab

100% Tumor Shrinkage at 2-months in advanced metastatic colorectal cancer was demonstrated by IMX-110 + BeiGene / Novartis anti-PD-1 Antibody Tislelizumab combination in the first, lowest dose cohort (two out of two first evaluable patients) in its ongoing phase 1b/2a dose escalation clinical tri...

IMMX - MBLY, NUWE and OMQS among mid-day movers

2023-04-27 12:24:19 ET Gainers: TOP Financial Group Limited ( TOP ) +186% . Evelo Biosciences ( EVLO ) +184% . ContraFect Corporation ( CFRX ) +68% . U Power Limited Ordinary Shares ( UCAR ) +40% . Atomera Incorporated ( ATOM ) +33...
IMMX - MBLY, NUWE and OMQS among mid-day gainers

2023-04-27 12:24:19 ET Gainers: TOP Financial Group Limited ( TOP ) +186% . Evelo Biosciences ( EVLO ) +184% . ContraFect Corporation ( CFRX ) +68% . U Power Limited Ordinary Shares ( UCAR ) +40% . Atomera Incorporated ( ATOM ) +33...

IMMX - ContraFect, Accuray top healthcare gainers; Baudax, 4D Molecular among losers

2023-04-27 10:01:57 ET Gainers: ContraFect ( CFRX ) +112% . Accuray ( ARAY ) +14% . Mainz Biomed ( MYNZ ) +15% . Mangoceuticals ( MGRX ) +14% . Immix Biopharma ( IMMX ) +9% . Losers: Baudax Bio ( BXRX ) -52% ....

IMMX - Immix Biopharma rises 11% after subsidiary Nexcella posts positive data from amyloidosis and multiple myeloma treatment

2023-04-27 09:38:46 ET Immix Biopharma's ( NASDAQ: IMMX ) subsidiary Nexcella released positive results from its ongoing Phase 1b/2 NEXICART-1 study on NXC-201, its autologous BCMA-targeted CAR-T cell therapy. to treat relapsed or refractory ( AL ) amyloidosis a...
IMMX - Nexcella, an Immix Biopharma subsidiary, Announces Positive 58-Patient NXC-201 Clinical Data: 100% Overall Response Rate in Light Chain (AL) Amyloidosis; 92% Overall Response Rate in Multiple Myeloma at the EBMT 49th Annual Meeting in Paris

Multiple Myeloma 92% was the overall response rate produced by NXC-201 in relapsed/refractory multiple myeloma patients treated at the therapeutic dose of 800 million CAR+T cells in its ongoing phase 1b/2a NEXICART-1 clinical trial (NCT04720313) who were not exposed to prior BCMA-targeted t...

IMMX - Nexcella, an Immix Biopharma subsidiary, announces poster presentation at the European Society for Blood and Marrow Transplantation 49th Annual Meeting

LOS ANGELES, April 04, 2023 (GLOBE NEWSWIRE) -- Nexcella Inc., a subsidiary of Immix Biopharma, Inc. (Nasdaq: IMMX) (“ImmixBio”, “Company”, “We” or “Us”) today announced that updated NXC-201 clinical data has been selected to be presented at...

IMMX - Nexcella, an Immix Biopharma Subsidiary, Announces 2023 Haematologica Editorial Highlighting NXC-201 Efficacy In The Context of U.S. Food And Drug Administration Approved BCMA CAR T Cells

LOS ANGELES, March 31, 2023 (GLOBE NEWSWIRE) -- Nexcella, Inc., a subsidiary of Immix Biopharma, Inc. (Nasdaq: IMMX) (“ImmixBio”, “Company”, “We” or “Us”) today announced that an editorial written by Maria Sjöstrand and Michel Sadelain ...
Previous 10 Next 10